Sign in to view content

APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies

Michael J Allingham, MD, PhD

Video
Published 2021

Related

Elamipretide, a Mitochondria-Targeted Drug for the Treatment of Vision Loss
Scott W. Cousins, MD
Updates from the Field
2019
Safety and Efficacy of Risuteganib in Intermediate Nonexudative AMD: First Time Results From a Phase 2 Study
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2019
Clinical Utility of the Fellow Eye in Patients With Bilateral GA Due to AMD: Long-Term Data from the Pegcetacoplan Clinical Program
Diana V Do, MD, FASRS
Updates from the Field
2025

Category: Diabetic Retinopathy

See more